Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human antibody RNase fusion protein targeting CD30+ lymphomas

30 Jan 2008

Abstract excerpt

Targeted RNases (TRs) are immunoenzymes with ribonucleases as cytotoxic effector domains, which are less immunogenic as plant or bacterial toxin components of classical immunotoxins. In this study, we show the generation and production of the first entirely human TR (huTR) directed against CD30+ lymphomas. The scFv-Fc-RNase construct was produced in human embryonic kidney (HEK) 293T cells, yielding up to 4 mg/L...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Lymphoma Diagnosis and Treatment
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18230757
DOI: 10.1182/blood-2007-04-082768

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human antibody RNase fusion protein targeting CD30+ lymphomasPMID 18230757Read ↗

Mechanism of action and therapeutic targeting of CD30 molecule in lymphomasSemantic proximity Read ↗

Mammalian cell display for rapid screening scFv antibody therapySemantic proximity Read ↗

A three dimensional human immune-tumor cell model reveals the importance of isotypes in antibody-based immunotherapySemantic proximity Read ↗

Single domain antibodies for the knockdown of cytosolic and nuclear proteinsSemantic proximity Read ↗

Engineering Human Pancreatic RNase 1 as an Immunotherapeutic Agent for Cancer Therapy Through Computational and Experimental Studies.Semantic proximity Read ↗

Development of unique cytotoxic chimeric antigen receptors based on human scFv targeting B7H6.Semantic proximity Read ↗

Construction of humanized anti-HER2 single-chain variable fragments (husFvs) and achievement of potent tumor suppression with the reconstituted husFv-Fdt-tBid immunoapoptotin.Semantic proximity Read ↗

Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell MalignanciesSemantic proximity Read ↗

Cytotoxicity of human RNase-based immunotoxins requires cytosolic access and resistance to ribonuclease inhibition.Semantic proximity Read ↗

Angiogenin mutants as novel effector molecules for the generation of fusion proteins with increased cytotoxic potential.Semantic proximity Read ↗

Engineering of ovine pancreatic RNase A as an Anti-tumor agent through in silico and experimental approaches.Semantic proximity Read ↗

Chimeric ribonuclease as a source of human adapter protein for targeted drug delivery.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.